Sai Life Sciences, a leading contract research, development, and manufacturing organisation (CRDMO), has completed Phase II of its Production Block 11 (PB-11) at the flagship API manufacturing facility in Bidar (Unit IV) in Karnataka.

With this addition of 91 KL in Q1 FY26, the block’s total capacity now reaches 200 KL, making PB-11 the largest single reactor volume block at the site. This expansion raises the facility’s overall installed reactor capacity to 700 KL. Krishna Kanumuri, CEO & Managing Director, stated: “This expansion at Bidar is more than additional capacity — it is about giving our partners the confidence that we can scale with their needs, deliver reliably, and adapt to the increasing complexity of their programs.”

PB-11 is a multi-purpose production block designed for large-scale commercial products. The Bidar Unit IV comprises 12 production blocks, high-potency API facilities, advanced QC labs, and specialized capabilities like lyophilization, cryogenic and high-pressure reactions. It is approved by USFDA, PMDA (Japan), and CDSCO (India). Since 2022, over 75 customer audits have validated Sai Life Sciences’ quality and compliance standards.